Relative risk estimates for transition between health states
| . | Tox → Rel . | TWiST → Rel . | TWiST → Death . | Rel → Death . |
|---|---|---|---|---|
| ASCT vs Chemo | 0.65 | 0.94 | 0.8 | 1.37* |
| LDH > N vs ≤N | 1.85* | 1.77* | 0.75 | 1.40* |
| Stage III-IV vs I-II | 1.36 | 2.44* | 1.1 | 1.15 |
| PS 2-4 vs 0-1 | 0.7 | 1.2 | 0.82 | 1.17 |
| . | Tox → Rel . | TWiST → Rel . | TWiST → Death . | Rel → Death . |
|---|---|---|---|---|
| ASCT vs Chemo | 0.65 | 0.94 | 0.8 | 1.37* |
| LDH > N vs ≤N | 1.85* | 1.77* | 0.75 | 1.40* |
| Stage III-IV vs I-II | 1.36 | 2.44* | 1.1 | 1.15 |
| PS 2-4 vs 0-1 | 0.7 | 1.2 | 0.82 | 1.17 |
Likelihood ratio test, P < .05.
ASCT indicates autologous stem cell transplantation; LDH, lactate dehydrogenase; PS, performance status; Rel, relapse period; Tox, toxicity period; TWiST, time without symptom and toxicity (TWiST).